R. Abdelnabi

The paper identifies ultrapotent SARS-CoV-2-neutralizing nanobodies that bind a conserved epitope on the spike protein, showing therapeutic efficacy in hamsters.

This study examines the genetic effects of effective and suboptimal dosing of mutagenic drugs on SARS-CoV-2 in hamsters, finding dose-dependent mutational load and no drug resistance.

This study shows that combining GS-441524 and molnupiravir significantly reduces SARS-CoV-2 viral load in infected Syrian hamsters.

This study shows that nirmatrelvir-resistant SARS-CoV-2 variants replicate and transmit efficiently in Syrian hamsters, highlighting the need for combination therapies to prevent resistance spread.

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

This paper identifies a potent human monoclonal antibody, P2G3, that neutralizes multiple SARS-CoV-2 variants including Omicron, and demonstrates its protective efficacy in a monkey model.

This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

The paper identifies potent anti-SARS-CoV-2 mAbs that cure infection in hamsters and demonstrates gene-based delivery for in vivo protection against variants.

This study shows an updated vaccine candidate provides full protection against multiple SARS-CoV-2 variants, prevents transmission, and induces neutralizing antibodies against Omicron in hamsters.

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

This study shows that bacterial cell wall components reduce alphavirus and flavivirus infectivity by directly interacting with viral particles in vitro.

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

This study compares the infectivity and pathogenicity of SARS-CoV-2 variants B.1.1.7 and B.1.351 to early 2020 strains in Syrian hamsters, finding similar disease outcomes but stronger proinflammatory cytokine elevation in B.1.1.7 infections.

This study evaluates ALG-097111, a selective SARS-CoV-2 3CLpro inhibitor, showing potent in vitro activity and significant in vivo antiviral effects in Syrian hamsters.

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

The paper shows that activating innate immune responses at the mosquito bite site, specifically targeting skin-resident macrophages, can inhibit systemic arbovirus dissemination and improve clinical outcomes.